title: Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.
abstract: Until recently, response assessment in patients with lymphoma was primarily performed by computed tomography (CT). Based on CT, International Workshop Criteria (IWC) were developed and widely used. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is a more sensitive and specific imaging technique for the detection of residual disease in lymphoma, and Revised Integrated International Workshop Criteria (IWC + PET) were recently proposed by the members of the International Harmonization Project (IHP), which combine both imaging techniques. We determined whether these new IWC + PET-criteria, can more accurately predict outcome compared to IWC-criteria in aggressive and indolent non-Hodgkin's lymphoma (NHL), and therefore correlated IWC and IWC + PET response with time-to-next-treatment (TNT) in 69 patients with NHL. We demonstrated that IWC + PET-guidelines are highly recommended over IWC-guidelines for patients with potentially-curable and routinely FDG-avid lymphoma. In contrast, no additional value of IWC + PET was demonstrated in a small group of patients with incurable histological subtypes.
authors: Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University Leuven, Leuven, Belgium. lieselot.brepoels@uz.kuleuven.ac.be
authors: Lieselot
authors: L
authors: Brepoels
authors: Sigrid
authors: S
authors: Stroobants
authors: Walter
authors: W
authors: De Wever
authors: Karoline
authors: K
authors: Spaepen
authors: Peter
authors: P
authors: Vandenberghe
authors: Jose
authors: J
authors: Thomas
authors: Anne
authors: A
authors: Uyttebroeck
authors: Luc
authors: L
authors: Mortelmans
authors: Christiane
authors: C
authors: De Wolf-Peeters
authors: Gregor
authors: G
authors: Verhoef
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002051:Burkitt Lymphoma / Q000000981:diagnostic imaging / Q000188:drug therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007391:International Cooperation; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000473:pathology; D049268:Positron-Emission Tomography; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18